References
- Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52
- Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349–56
- Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor family. N Engl J Med 1996; 334: 1717–25
- Pitts SA, Olomolative OO, Elson CJ, Westacott CI, Bidwell JL. An Msp A1 polymorphism in exon 1 of the human TNF receptor type 1 (p55) gene. Euro J Immunol 1998; 25: 269–70
- A1-Ansari AS, Ollier WE, Villarreal J, Ordi J, The LS, Hajeer AH. Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 2000; 55: 97–9
- Bridges SL, Jeng G, Jr, Moran M, Kuffner T, Whitworth WC, McNicholl J. Single nucleotide polymorphisms in tumor necrosis factor receptor genes: definition of novel haplotypes and racial/ethnic difference. Arthritis Rheum 2002; 46: 2045–50
- Barton A, John S, Ollier WER, Silman A, Worthington J. Association between rheumatoid arthritis and polymorphism of tumor necrosis factor II, but not tumor necrosis factor I, in Caucasians. Arthritis Rheum 2001; 44: 61–5
- Laval SH, Timms A, Edwards S, Bradbury L, Brophy S, Milicic A, et al. Whole genome screening in ankylosing spondylitis: evidence of non-MHC genetic susceptibility loci. Am J Hum Genet 2001; 68: 918–26